ReviewFuture science OA2026
Global technological trends in sustainable antimicrobial surface formulations: a patent-based review for cleaner healthcare environments.
Review in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHealthcare-associated infections (HAIs) are a global challenge, exacerbated by multidrug-resistant pathogens. This study systematically maps antimicrobial surface formulations (1995-2024), analyzing gaps in regulatory readiness, toxicological validation, and sustainability. AREAS COVERED: Using the Espacenet database and PRISMA guidelines, 49 patents were analyzed. Innovation surged post-2015, led by private corporations (72.09%) in the USA, Canada, and China (67.35%). Synthetic actives, primarily quaternary ammonium compounds, dominated (71.43%), while natural (16.33%) and hybrid (10.20%) approaches were less frequent. Key targets included EXPERT OPINION: A significant gap exists between technological innovation and regulatory/safety validation. Future developments must integrate life-cycle assessments and robust toxicological testing. Harmonized regulatory pathways and public-private partnerships are essential to translate these innovations into scalable, sustainable, and safer disinfectant solutions for healthcare environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.